IN SILICO SCREENING OF POTENT PPARGAMMA AGONISTS AMONG NATURAL ANTICANCER COMPOUNDS OF INDIAN ORIGIN

Authors

  • Hemanth Gurula VRR Institute of Biomedical Science (Affiliated to University of Madras)
  • Tholcopiyan Loganathan VRR Institute of Biomedical Science (Affiliated to University of Madras)
  • Yaongamphi Vashum VRR Institute of Biomedical Science (Affiliated to University of Madras)
  • Sudha Pannerselvam VRR Institute of Biomedical Science (Affiliated to University of Madras)
  • Umashankar Vetrivel Vision Research Foundation, Sankara Nethralaya
  • Shila Samuel VRR Institute of Biomedical Science (Affiliated to University of Madras)

Abstract

ABSTRACT
Objective: Naturally occurring anticancer compounds of Indian origin are well-known for potential therapeutic values. A better understanding of
the intermolecular interactions of these compounds with peroxisome proliferator-activated receptor gamma (PPARγ) is essential, as its activity is
reported in many of the cancers involving colon, breast, gastric, and lung. By this study, it is attempted to perform an in silico screening of natural
anticancer compounds of Indian origin with PPARγ ligand binding domain (LBD). The potential anticancer leads ranked in this study will also exert
an additional advantage of PPARγ activity modulation. As PPARγ is also an important nuclear hormone receptor that modulates transcriptional
regulation of lipid and glucose homeostasis and also a key target for many of the anti-diabetic medications, the compounds ranked by this study will
also be utilized for other related therapeutic effects.
Methods: This study features in silico screening of compounds from Indian Plant Anticancer compounds database against PPARγ LBD main performed
Schrodinger glide virtual screening and docking module to delineate potential PPARγ agonists. Finally, the most potential lead was also subjected to
molecular dynamics simulation to infer the stability of complex formation.
Results: The results reveal that majority of the top ranking compounds that interact with LBD was found to be flavonoids, and all these compounds
were found to interact with key residues involved in PPARγ agonist interactions.
Conclusion: The leads from this study would be helpful in better understanding of the potential of naturally occurring anticancer compounds of
Indian origin toward targeting PPARγ.
Keywords: Peroxisome proliferator-activated receptor-gamma, Agonists, Docking, Natural compounds, Anticancer.

 

Author Biographies

Hemanth Gurula, VRR Institute of Biomedical Science (Affiliated to University of Madras)

Research Scholar
Department of Biochemistry

Tholcopiyan Loganathan, VRR Institute of Biomedical Science (Affiliated to University of Madras)

Research Scholar
Department of Biochemistry

Yaongamphi Vashum, VRR Institute of Biomedical Science (Affiliated to University of Madras)

Research Scholar
Department of Biochemistry

Sudha Pannerselvam, VRR Institute of Biomedical Science (Affiliated to University of Madras)

Research Scholar
Department of Biochemistry

Umashankar Vetrivel, Vision Research Foundation, Sankara Nethralaya

Reader
Department of Bioinformatics

Shila Samuel, VRR Institute of Biomedical Science (Affiliated to University of Madras)

Head & Research Scientist
Department of Biochemistry

References

REFERENCES

Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev

Med 2002;53:409-35.

Boitier E, Gautier JC, Roberts R. Advances in understanding the

regulation of apoptosis and mitosis by peroxisome-proliferator

activated receptors in pre-clinical models: Relevance for human health

and disease. Comp Hepatol 2003;2(1):3.

Yu S, Reddy JK. Transcription coactivators for peroxisome proliferatoractivated

receptors. Biochim Biophys Acta

;1771(8):936-51.

Feige JN, Auwerx J. Transcriptional coregulators in the control of

energy homeostasis. Trends Cell Biol 2007;17(6):292-301.

Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in

fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

Cell 1994;79(7):1147-56.

Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. Differentiationdependent

expression of the brown adipocyte uncoupling protein gene:

Regulation

by

peroxisome

proliferator-activated

receptor

gamma.

Mol

Cell Biol 1996;16(7):3410-9.

Dussault I, Forman BM. Prostaglandins and fatty acids regulate

transcriptional signaling via the peroxisome proliferator activated

receptor nuclear receptors. Prostaglandins Other Lipid Mediat

;62(1):1-13.

Evans RM, Barish GD, Wang YX. PPARs and the complex journey to

obesity. Nat Med 2004;10(4):355-61.

Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and

mouse physiology. Biochim Biophys Acta 2007;1771(8):999-1013.

Tontonoz P, Spiegelman BM. Fat and beyond: The diverse biology of

PPAR gamma. Annu Rev Biochem 2008;77:289-312.

Kamijo Y, Nicol CJ, Alexson SE. Pharmacological and toxicological

advances in PPAR-related medicines. PPAR Res 2012;2012:940-64.

Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA,

et al. Loss-of-function mutations in PPAR gamma associated with

human colon cancer. Mol Cell 1999;3(6):799-804.

Perumal PC, Sowmya S, Pratibha P, Vidya B, Anusooriya P, Starlin T,

et al. Identification of novel PPARγ agonist from GC-MS analysis of

ethanolic extract of Cayratia trifolia (L.): A computational molecular

simulation studies. J Appl Pharm Sci 2014;4(09):006-11.

Asian J Pharm Clin Res, Vol 9, Issue 4, 2016, 320-324

Gurula et al.

Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond

peroxisome proliferator-activated receptor gamma signaling: The

multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat

Cancer 2006;13(2):401-13.

Sikka S, Chen L, Sethi G, Kumar AP. Targeting PPAR? signaling

cascade for the prevention and treatment of prostate cancer. PPAR Res

;2012:968040.

Pignatelli M, Sánchez-Rodríguez J, Santos A, Perez-Castillo A

-deoxy-Delta-12,14-prostaglandin J2 induces programmed cell death

of breast cancer cells by a pleiotropic mechanism. Carcinogenesis

;26(1):81-92.

Venkatachalam G, Kumar AP, Sakharkar KR, Thangavel S, Clement MV,

Sakharkar MK. PPAR? Disease gene network and identification of

therapeutic targets for prostate cancer. J Drug Target 2011;19(9):781-96.

Velmurugan P, Kamaraj M, Prema D. Phytochemical constituents of

Cadaba trifoliata Roxb. Root extract. Int J Phytomed 2010;2(4):379-84.

Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai

T, et al. Antitumor activity of a novel podophyllotoxin derivative

(TOP-53) against lung cancer and lung metastatic cancer. Cancer Res

;56(12):2809-14.

Kepler JA, Wani MC, McNaull JN, Wall ME, Levine SG. Plant antitumor

agents. IV. An approach toward the synthesis of camptothecin. J Org

Chem 1969;34(12):3853-8.

Cragg GM, Newman DJ. Plants as a source of anti-cancer agents.

J Ethnopharmacol 2005;100(1-2):72-9.

Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr. The vinca alkaloids:

A new class of oncolytic agents. Cancer Res 1963;23:1390-427.

Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT,

et al. Flavopiridol induces apoptosis of normal lymphoid cells,

causes immunosuppression, and has potent antitumor activity In

vivo against human leukemia and lymphoma xenografts. Blood

;91(7):2482-90.

Vetrivel U, Subramanian N, Pilla K. In PACdb – Indian plant anticancer

compounds database. Bioinformation 2009;4(2):71-4.

Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X,

Malainer C, et al. Natural product agonists of peroxisome proliferatoractivated

receptor gamma (PPARγ): A review. Biochem Pharmacol

;92(1):73-89.

Gurula H, Loganathan T, Krishnamoorthy T, Vetrivel U, Samuel S.

Virtual screening studies of seaweed metabolites for predicting

potential PPARγ agonists. Int J Pharm Pharm Sci 2015;7(10):268-71.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental

and computational approaches to estimate solubility and permeability

in drug discovery and development settings. Adv Drug Deliv Rev

;46(1-3):3-26.

Youssef J, Badr M. Peroxisome proliferator-activated receptors and

cancer: Challenges and opportunities. Br J Pharmacol 2011;164(1):68-82.

Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK,

Milburn MV, et al. Asymmetry in the PPARgamma/RXRalpha crystal

structure reveals the molecular basis of heterodimerization among

nuclear receptors. Mol Cell 2000;5(3):545-55.

Lewis SN, Garcia Z, Hontecillas R, Bassaganya-Riera J, Bevan DR.

Pharmacophore modeling improves virtual screening for novel

peroxisome proliferator-activated receptor-gamma ligands. J Comput

Aided Mol Des 2015;29(5):421-39.

Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, et al. Structural

basis for the activation of PPARgamma by oxidized fatty acids. Nat

Struct Mol Biol 2008;15(9):924-31.

Chen KC, Chen CY. In Silico identification of potent PPAR-? Agonists

from traditional Chinese medicine: A bioactivity prediction, virtual

screening, and molecular dynamics study. Evid Based Complement

Alternat Med 2014;2014:192452.

Saptarini NM, Saputri FA, Levita J. Molecular modeling study of

PPARγ agonists: Dehydro-di-isoeugenol, macelignan, pioglitazone,

netoglitazone, and rosiglitazone as antidiabetic drugs. Int J Chem

;6(2):48.

Miller EG, Peacock JJ, Bourland TC, Taylor SE, Wright JM, Patil BS,

et al. Inhibition of oral carcinogenesis by citrus flavonoids. Nutr Cancer

;60(1):69-74.

López-Lázaro M. Distribution and biological activities of the flavonoid

luteolin. Mini Rev Med Chem 2009;9(1):31-59.

Melstrom LG, Salabat MR, Ding XZ, Milam BM, Strouch M,

Pelling JC, et al. Apigenin inhibits the GLUT-1 glucose transporter and

the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer

cells. Pancreas 2008;37(4):426-31.

Park JH, Jin CY, Lee BK, Kim GY, Choi YH, Jeong YK. Naringenin

induces apoptosis through downregulation of Akt and caspase-3

activation in human leukemia THP-1 cells. Food Chem Toxicol

;46(12):3684-90.

Privat M, Aubel C, Arnould S, Communal Y, Ferrara M, Bignon YJ.

Breast cancer cell response to genistein is conditioned by BRCA1

mutations. Biochem Biophys Res Commun 2009;379(3):785-9.

Li W, Du B, Wang T, Wang S, Zhang J. Kaempferol induces apoptosis

in human HCT116 colon cancer cells via the Ataxia-telangiectasia

mutated-p53 pathway with the involvement of p53 upregulated

modulator of apoptosis. Chem Biol Interact 2009;177(2):121-7.

Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, et al.

Wedelolactone suppresses LPS-induced caspase-11 expression

by directly inhibiting the IKK complex. Cell Death Differ

;11(1):123-30.

Published

2016-07-01

How to Cite

Gurula, H., T. Loganathan, Y. Vashum, S. Pannerselvam, U. Vetrivel, and S. Samuel. “IN SILICO SCREENING OF POTENT PPARGAMMA AGONISTS AMONG NATURAL ANTICANCER COMPOUNDS OF INDIAN ORIGIN”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 4, July 2016, pp. 320-4, https://innovareacademics.in/journals/index.php/ajpcr/article/view/12265.

Issue

Section

Original Article(s)